Characterization of Immune Responses to rAAVrh8 Gene Therapy for GM2 Gangliosidosis in Phase 1/2 Trial
Preprint
- 29 May 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Understanding how the immune system responds to adreno-associated virus (AAV) gene therapy and potentially modulating that response is vital to their safety and ultimate success. However, the immune response in the central nervous system (CNS) to AAV gene therapy is still not well understood. Here, we characterized the immune responses to AAVrh8 vectors injected into the thalamus and cerebral spinal fluid (CSF) of Tay-Sachs (TSD) and Sandhoff (SD) disease patients. Nine patients in four dose cohorts were treated with gene therapy while being immunosuppressed with rituximab, sirolimus and prednisolone. Neutralizing antibodies against AAV capsid were detected in the serum of 9/9 patients and in the CSF of 7/9 patients. Specific T-cell responses against the AAV capsid were documented in all patients, with most patients developing responses at 2–3 weeks post-injection. Flow cytometry suggested the induction of capsid-specific regulatory T-cells in the periphery. Local immune responses were detected by cytokine analysis of the CSF along with upregulation of several chemokines, including CXCL8, CXCL9 and CXCL10. These Phase I/II clinical trial data provide valuable insights into how the human immune system responds to direct administration of AAV into the CNS and important assessments on the efficacy of the immune suppression regimen which can be used to inform future AAV clinical trials.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- The curious case of AAV immunologyMolecular Therapy, 2025
- Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?Neurotherapeutics, 2024
- Brain resident memory T cells rapidly expand and initiate neuroinflammatory responses following CNS viral infectionBrain, Behavior, and Immunity, 2023
- Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene TransferBioDrugs, 2023
- 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin DeficiencyMolecular Therapy, 2017
- Immune Heterogeneity in Neuroinflammation: Dendritic Cells in the BrainJournal of Neuroimmune Pharmacology, 2012
- Immune surveillance in the central nervous systemNature Neuroscience, 2012
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseNature Medicine, 2006
- Elaborate interactions between the immune and nervous systemsNature Immunology, 2004
- The startle response and serum enzyme profile in early detection of Tay-Sachs' diseaseThe Journal of Pediatrics, 1964